<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1665-5044</journal-id>
<journal-title><![CDATA[Revista mexicana de neurociencia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. neurocienc.]]></abbrev-journal-title>
<issn>1665-5044</issn>
<publisher>
<publisher-name><![CDATA[Academia Mexicana de Neurología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1665-50442019000600284</article-id>
<article-id pub-id-type="doi">10.24875/rmn.19000073</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Neurotoxicity of calcineurin inhibitors: Tacrolimus]]></article-title>
<article-title xml:lang="es"><![CDATA[Neurotoxicidad de los inhibidores de la calcineurina: tacrolimus]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Flores-Aldama]]></surname>
<given-names><![CDATA[Marco J.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Flores-Silva]]></surname>
<given-names><![CDATA[Fernando D.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Departamento de Neurología y Psiquiatría ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<volume>20</volume>
<numero>6</numero>
<fpage>284</fpage>
<lpage>287</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1665-50442019000600284&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1665-50442019000600284&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1665-50442019000600284&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract At the beginning of this century, calcineurin inhibitors, especially tacrolimus, were the treatment of choice for immunosuppression in solid organs. It is known that in recent years, the incidence of renal and hepatic transplants has increased up to 15%, and therefore, a compelling reason why immunosuppression treatment is more relevant to reduce rejection, morbidity, and mortality rates. Although the systemic complications of the use of calcineurin inhibitors are known, there is still little information on its neurotoxic effects; however, a prevalence in up to 28% is estimated with a broad spectrum of clinical and radiological manifestations. The relevance of this work lies in describing the phenomenon of neurotoxicity, its clinical and radiological manifestations, risk factors, and management.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen A principios de este siglo, los inhibidores de la calcineurina, especialmente el tacrolimus, eran el tratamiento de elección para la inmunosupresión en órganos sólidos. Se sabe que en los últimos años, la incidencia de trasplantes renales y hepáticos ha aumentado hasta un 15% y, por lo tanto, una razón poderosa por la cual el tratamiento de inmunosupresión es más relevante para reducir las tazas de rechazo, morbilidad y mortalidad. Aunque se conocen las complicaciones sistémicas del uso de inhibidores de calcineurina, todavía hay poca información sobre sus efectos neurotóxicos. Sin embargo, se estima una prevalencia de hasta el 28% con un amplio espectro de manifestaciones clínicas y radiológicas. La relevancia de este trabajo radica en describir el fenómeno de la neurotoxicidad, sus manifestaciones clínicas y radiológicas, factores de riesgo y gestión.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Neurotoxicity]]></kwd>
<kwd lng="en"><![CDATA[Tacrolimus]]></kwd>
<kwd lng="en"><![CDATA[Tremor]]></kwd>
<kwd lng="en"><![CDATA[Transplant]]></kwd>
<kwd lng="es"><![CDATA[Neurotoxicidad]]></kwd>
<kwd lng="es"><![CDATA[Tacrolimus Temblor]]></kwd>
<kwd lng="es"><![CDATA[Trasplante]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ekberg]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Tedesco-Silva]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Demirbas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vítko]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nashan]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Gürkan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reduced exposure to calcineurin inhibitors in renal transplantation]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2007</year>
<volume>357</volume>
<page-range>2562-75</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bechstein]]></surname>
<given-names><![CDATA[WO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neurotoxicity of calcineurin inhibitors:impact and clinical management]]></article-title>
<source><![CDATA[Transpl Int]]></source>
<year>2000</year>
<volume>13</volume>
<page-range>313-26</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mueller]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Platz]]></surname>
<given-names><![CDATA[KP]]></given-names>
</name>
<name>
<surname><![CDATA[Bechstein]]></surname>
<given-names><![CDATA[WO]]></given-names>
</name>
<name>
<surname><![CDATA[Schattenfroh]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Stoltenburg-Didinger]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Blumhardt]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neurotoxicity after orthotopic liver transplantation A comparison between cyclosporine and FK506]]></article-title>
<source><![CDATA[Transplantation]]></source>
<year>1994</year>
<volume>58</volume>
<page-range>155-70</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kershner]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Fitzsimmons]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation]]></article-title>
<source><![CDATA[Transplantation]]></source>
<year>1996</year>
<volume>62</volume>
<page-range>920-6</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brooks]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Tett]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Isbel]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Staatz]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Population pharmacokinetic modelling and Bayesian estimation of tacrolimus exposure:is this clinically useful for dosage prediction yet?]]></article-title>
<source><![CDATA[Clin Pharmacokinet]]></source>
<year>2016</year>
<volume>55</volume>
<page-range>1295-335</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Woillard]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Saint-Marcoux]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Debord]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Åsberg]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacokinetic models to assist the prescriber in choosing the best tacrolimus dose]]></article-title>
<source><![CDATA[Pharmacol Res]]></source>
<year>2018</year>
<volume>130</volume>
<page-range>316-21</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Erro]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bacchin]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Magrinelli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Tomei]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Geroin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Squintani]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tremor induced by calcineurin inhibitor immunosuppression:a single-centre observational study in kidney transplanted patients]]></article-title>
<source><![CDATA[J Neurol]]></source>
<year>2018</year>
<volume>265</volume>
<page-range>1676-83</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McDonald]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Goldberg]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Gwag]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chi]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cyclosporine induces neuronal apoptosis and selective oligodendrocyte death in cortical cultures]]></article-title>
<source><![CDATA[Ann Neurol]]></source>
<year>1996</year>
<volume>40</volume>
<page-range>750-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guarino]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Stracciari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pazzaglia]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sterzi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Santilli]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Donato]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neurological complications of liver transplantation]]></article-title>
<source><![CDATA[J Neurol]]></source>
<year>1996</year>
<volume>243</volume>
<page-range>137-42</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sander]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lyson]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
<name>
<surname><![CDATA[Victor]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sympathetic neural mechanisms of cyclosporine-induced hypertension]]></article-title>
<source><![CDATA[Am J Hypertens]]></source>
<year>1996</year>
<volume>9</volume>
<page-range>121S-38</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wijdicks]]></surname>
<given-names><![CDATA[EF]]></given-names>
</name>
<name>
<surname><![CDATA[Wiesner]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Dahlke]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Krom]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[FK506-induced neurotoxicity in liver transplantation]]></article-title>
<source><![CDATA[Ann Neurol]]></source>
<year>1994</year>
<volume>35</volume>
<page-range>498-501</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fryer]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Fortier]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Metrakos]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Verran]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Asfar]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Pelz]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Central pontine myelinolysis and cyclosporine neurotoxicity following liver transplantation]]></article-title>
<source><![CDATA[Transplantation]]></source>
<year>1996</year>
<volume>61</volume>
<page-range>658-61</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bronster]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Emre]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mor]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Sheiner]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neurologic complications of orthotopic liver transplantation]]></article-title>
<source><![CDATA[Mt Sinai J Med]]></source>
<year>1994</year>
<volume>61</volume>
<page-range>63-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
